- Trump’s Executive Order on Drug Prices Might Be More in Favour of Drug Companies
- The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?
- In Thailand, patient activism is crucial to expanding treatment
- The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest
- June 2017 Alert: Pressure on countries hiked by US on IP
Category Archives: R&D
Lawmakers are concerned that giving a drug company a monopoly on the promising vaccine could make it unaffordable.
US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices
By Frederick M Abbott*, IP Watch | 31/05/2017 The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. … Continue reading
Appeal from Asian Civil Society to the DG to discuss the report of United Nations Secretary-General’s High-Level Panel on Access to Medicines (HLP) at the forthcoming EB
Dr. Margaret Chan, Director-General, World Health Organization, Switzerland Dr Poonam Khetrapal Singh, Regional Director of WHO South-East Asia Region, New Delhi Dr. Raymond Busuttil, Chairman of the Executive Board, World Health Organization 18 November 2016 Re: Appeal from Asian Civil Society to … Continue reading
By JASON CONE and RAYMOND C. OFFENHEISER, The New York Times|OCT. 27, 2016 Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the … Continue reading